October 17, 2025

Universität Heidelberg: Successful Placement in Times Higher Education Rankings

Universität Heidelberg: Successful Placement in Times Higher Education Rankings

Ruperto Carola is ranked among the world’s “Top 50” and one of the top three universities in Germany

Heidelberg University is one of the top three universities in Germany, ranking third in the 2025/2026 Times Higher Education World University Rankings, which have just been published. In 49th position internationally, it is among the world’s “Top 50” as in the previous year – one of only three German universities to earn that distinction. In the Europe-wide comparison, Ruperto Carola is placing 13th in the THE Rankings.

In Germany, Heidelberg University is among the “Top 50” universities in the world, along with the two universities in Munich. Taking first place at the national level, Technical University of Munich ranks 27th internationally. LMU Munich, second in Germany, is in 34th position in the global comparison. Five other German universities are among the “Top 100” universities, ranked 89th, 91st, 92nd (shared) and 98th.

The Times Higher Education (THE) World University Rankings, published on 9 October 2025, are based on a total of 18 different indicators. They are grouped into five areas of performance. These are, above all, teaching (learning environment), research environment and research quality. Other areas analyzed include aspects of internationalization and industry. This year’s THE Rankings feature 2,191 institutions from 115 countries/regions.

Further information

Our latest News

discover more
AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

NORTH CHICAGO, Ill., July 6, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 […]

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

It should be biofunctional – that is, it should replicate the natural cellular environment as closely as possible – and it should be printable: bioink. Achieving both of these properties at the same time is an enormous challenge that conventional biomaterials often fail to meet. Together with two partner companies, researchers at the NMI have now taken an important […]

New AI System Provides Treatment Recommendations for Complex Blood Cancers

New AI System Provides Treatment Recommendations for Complex Blood Cancers

Researchers from the German Cancer Research Center (DKFZ), the HI-STEM* Stem Cell Institute, and the Heidelberg University Hospital (UKHD) have developed “HemaGuide,” an AI assistant that supports physicians in making difficult treatment decisions. In extensive testing, the system has shown a high degree of agreement with the recommendations of experienced experts and could significantly improve […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp